Advances in the delivery of buprenorphine for opioid dependence
| Autor: | Viral V Goradia, Richard N. Rosenthal |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
drug diversion
Agonist medicine.drug_class maintenance therapy Pharmaceutical Science depot medications Review treatment adherence Partial agonist 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Drug Discovery Opiate Substitution Treatment Animals Humans Medicine 030212 general & internal medicine Dosing Pharmacology business.industry opioid use disorder Opioid overdose Opioid use disorder drug implants Drug diversion Opioid-Related Disorders buprenorphine medicine.disease Analgesics Opioid Opioid Delayed-Action Preparations Anesthesia business 030217 neurology & neurosurgery Buprenorphine medicine.drug |
| Zdroj: | Drug Design, Development and Therapy |
| ISSN: | 1177-8881 |
| DOI: | 10.2147/dddt.s72543 |
| Popis: | Opioid use disorders (OUDs) have long been a global problem, but the prevalence rates have increased over 20 years to epidemic proportions in the US, with concomitant increases in morbidity and all-cause mortality, but especially opioid overdose. These increases are in part attributable to a several-fold expansion in the prescription of opioid pain medications over the same time period. Opioid detoxification and psychosocial treatments alone have each not yielded sufficient efficacy for OUD, but μ-opioid receptor agonist, partial agonist, and antagonist medications have demonstrated the greatest overall benefit in OUD treatment. Buprenorphine, a μ-opioid receptor partial agonist, has been used successfully on an international basis for several decades in sublingual tablet and film preparations for the treatment of OUD, but the nature of formulation, which is typically self-administered, renders it susceptible to nonadherence, diversion, and accidental exposure. This article reviews the clinical trial data for novel buprenorphine delivery systems in the form of subcutaneous depot injections, transdermal patches, and subdermal implants for the treatment of OUD and discusses both the clinical efficacy of longer-acting formulations through increasing consistent medication exposure and their potential utility in reducing diversion. These new delivery systems also offer new dosing opportunities for buprenorphine and strategies for dosing intervals in the treatment of OUD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|